Key Highlights
- TPST shares fell sharply in a single session, without a clearly identifiable, individually confirmed public catalyst tied to that specific session.
- Tempest has publicly repositioned around an in vivo CAR-T strategy during 2026, layered over its historical lead asset amezalpat for liver cancer.
- TPST trades near $0.91 with a market Capitalization around $14.5 million and roughly 16 million shares outstanding following a 1-for-13 reverse split.
- Reports indicated Tempest struggled to find a partner or buyer to fund amezalpat's late-stage development, weighing on the Investment case.
Clinical-stage biotech can turn on a single strategic decision, and Tempest Therapeutics, Inc (NASDAQ: TPST) has spent 2026 illustrating exactly that. Once defined by its liver-cancer candidate amezalpat, the Nasdaq-listed micro-cap has pivoted toward a next-generation cell-therapy strategy while its share price has collapsed to well under a dollar. A steep single-session decline raises the familiar question for a company in transition: is the weakness a warning about survival, or the market repricing an early-stage reset?
Company and Latest Development
Tempest Therapeutics is a small clinical-stage oncology company. Its historical lead program, amezalpat (TPST-1120), a PPAR-alpha antagonist, generated Phase 2 data in first-line unresectable or metastatic hepatocellular carcinoma (liver cancer), and the company had signalled an intent to advance the asset toward later-stage development. During 2026, however, Tempest publicly repositioned around an in vivo CAR-T strategy, describing next-generation cell-therapy work and disclosing collaboration activity as it seeks to advance that platform toward the clinic. The shift reflects the pressures on a capital-constrained developer: rather than fund an expensive Phase 3 liver-cancer program alone, the company has emphasised a newer pipeline direction while it works to secure resources.
What Is Driving Attention Around TPST?
The single-day drop does not have a clearly identifiable, individually confirmed public catalyst tied to that specific session. For a sub-dollar micro-cap, daily swings frequently reflect thin liquidity, financing overhang and shifting sentiment rather than a discrete announcement. The broader context is more telling: the stock has fallen dramatically from a 52-week high above $12 to under $1, and the company implemented a Reverse Stock Split during its restructuring. Reports also indicated that Tempest struggled to find a partner or buyer to fund amezalpat's late-stage development, which weighed on the investment case even as management outlined its new cell-therapy focus.
Key Numbers and Company Position
The verifiable financial picture is that of a distressed, pre-revenue developer. TPST trades on Nasdaq near $0.91, with a market capitalization around $14.5 million and roughly 16 million shares outstanding following a 1-for-13 reverse split. As a clinical-stage company, Tempest reports no product Revenue and has posted substantial net losses, with a reported annual net loss in the tens of millions of dollars. The 52-week range stretching from above $12 to under $1 underscores severe value erosion and dilution.
What Could Come Next?
Several company-specific items could shape sentiment. Investors may watch for concrete progress on the in vivo CAR-T strategy, including any move toward a first clinical study, plus updates on collaborations and any decision on amezalpat's future, whether partnered, out-licensed or shelved. Financing is the pivotal variable: as a cash-constrained micro-cap, Tempest will likely need additional capital, so any raise, Partnership or strategic transaction would be highly material.
Risks to Watch
The risks are considerable. Tempest faces high clinical and scientific uncertainty as it shifts toward an unproven, early cell-therapy platform, with no guarantee any candidate reaches or advances through the clinic. Funding pressure is acute; further capital raises could dilute existing holders significantly. Sub-dollar trading brings Liquidity and listing-compliance risk, and the difficulty of financing amezalpat's late-stage development highlights execution and partnership risk.
Financing and Cell-Therapy Progress Will Determine Whether This Is a Genuine Reset
Tempest Therapeutics enters late 2026 as a repositioned, high-risk micro-cap trading well under a dollar, with a new in vivo CAR-T emphasis layered over a liver-cancer program that struggled to attract partners. The decline has no single confirmed catalyst and fits the pattern of a distressed clinical-stage name. The developments worth monitoring are concrete: financing, cell-therapy progress, amezalpat's fate and listing compliance will determine whether this proves a genuine reset or a deeper warning.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...